Expression data from patients with HCC receiving Nivolumab

We have generated an immune classifier able to identify patients belonging to the immune subclass of HCC. Characteristics of the immune subclass resemble those of patients who most respond to immunotherapy. We performed microarray expression of the tumors of two patients before starting treatment with nivolumab to verify if the immune classifier generated was able to predict response to immunotherapy. Upon patients’ consent, RNA extraction and RNA profiling were performed on tumoral sections derived from available archived tissues collected any time before treatment.